Expression of FUS-CHOP fusion protein in immortalized/transformed human mesenchymal stem cells drives mixoid liposarcoma formation

Stem Cells

Volumn 31, Issue 10, 2013, Pages 2061-2072

  Rodriguez, Rene ^a   Tornin, Juan ^a   Suarez, Carlos ^a   Astudillo, Aurora ^b   Rubio, Ruth ^c   Yauk, Carole ^d   Williams, Andrew ^d   Rosu Myles, Michael ^e   Funes, Juan M ^f   Boshoff, Chris ^a   Menendez, Pablo ^a,c,g,h  

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

^d Environmental Health Center   (Canada)

^e HEALTH CANADA   (Canada)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF BARCELONA   (Spain)

^h INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

FUS CHOP; Mesenchymal stromal stem cells; Mixoid liposarcoma; Oncogenic hits; Sarcomagenesis

Indexed keywords

FUSED IN SARCOMA PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HYBRID PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DIFFERENTIATION; FUSION GENE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LIPOSARCOMA; MESENCHYMAL STEM CELL; MOUSE; MYXOSARCOMA; NONHUMAN; ONCOGENE C MYC; ONCOGENE H RAS; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

FUS-CHOP; MESENCHYMAL STROMAL/STEM CELLS; MIXOID LIPOSARCOMA; ONCOGENIC HITS; SARCOMAGENESIS;

ADIPOGENESIS; ANIMALS; CARCINOGENESIS; CELL LINE, TRANSFORMED; GENE EXPRESSION; HUMANS; LIPOSARCOMA, MYXOID; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; ONCOGENE PROTEINS, FUSION; RNA-BINDING PROTEIN FUS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR CHOP; TRANSCRIPTOME;

EID: 84887925395     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1472     Document Type: Article

References (53)

1. Garcia-Castro J., Trigueros C, Madrenas J et al. Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. J Cell Mol Med 2008;12:2552-2565.
2. Rodriguez R, Garcia-Castro J, Trigueros C et al. Multipotent mesen-chymal stromal cells: Clinical applications and cancer modeling. Adv Exp Med Biol 2012;741:187-205.
3. Rodriguez R, Rubio R, Menendez P. Modeling sarcomagenesis using multipotent mesenchymal stem cells. Cell Res 2012;22:62-67.
4. Riggi N, Cironi L, Provero P et al. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 2005;65:11459-11468.
5. Lin PP, Pandey MK, Jin F et al. EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Res 2008;68:8968-8975.
6. Charytonowicz E, Terry M, Coakley K et al. PPARgamma agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. J Clin Invest 2012; 122:886-898.
7. Perez-Losada J., Pintado B, Gutierrez-Adan A et al. The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice. Oncogene 2000;19:2413-2422.
8. Riggi N, Cironi L, Provero P et al. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res 2006;66:7016-7023.
9. Rodriguez R, Rubio R, Gutierrez-Aranda I et al. FUS-CHOP fusion protein expression coupled to p53 deficiency induces liposarcoma in mouse but not in human adipose-derived mesenchymal stem/stromal cells. Stem Cells 2011;29:179-192.
10. Ren YX, Finckenstein FG, Abdueva DA et al. Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res 2008;68:6587-6597.
11. Keller C, Arenkiel BR, Coffin CM et al. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: Cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 2004;18:2614-2626.
12. Haldar M, Hancock JD, Coffin CM et al. A conditional mouse model of synovial sarcoma: Insights into a myogenic origin. Cancer Cell 2007;11:375-388.
13. Riggi N, Suva ML, Suva D et al. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 2008;68:2176-2185.
14. Cironi L, Provero P, Riggi N et al. Epigenetic features of human mes-enchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1. PLoS One 2009;4: e7904.
15. Fletcher O, Houlston RS Architecture of inherited susceptibility to common cancer. Nat Rev Cancer 2010;10:353-361.
16. Singer S, Nielsen T, Antonescu C. Molecular biology of soft tissue sarcoma. In: DeVita V, Lawrence T, Rosenberg S, eds. Cancer: Principles & Practice of Oncology. 9th ed. Philadelphia: Wolters, 2011: 1522-1532.
17. Sanchez-Garcia I., Rabbitts TH Transcriptional activation by TAL1 and FUS-CHOP proteins expressed in acute malignancies as a result of chromosomal abnormalities. Proc Natl Acad Sci USA 1994;91: 7869-7873.
18. Ron D, Habener JF CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev 1992;6:439-453.
19. Perez-Mancera P.A., Bermejo-Rodriguez C, Sanchez-Martin M et al. FUS-DDIT3 prevents the development of adipocytic precursors in lip-osarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E. PLoS One 2008;3:e2569.
20. Rubio R, Garcia-Castro J, Gutierrez-Aranda I et al. Deficiency in p53 but not retinoblastoma induces the transformation of mesenchymal stem cells in vitro and initiates leiomyosarcoma in vivo. Cancer Res 2010;70:4185-4194.
21. Funes JM, Quintero M, Henderson S et al. Transformation of human mesenchymal stem cells increases their dependency on oxidative phos-phorylation for energy production. Proc Natl Acad Sci USA 2007;104: 6223-6228.
22. Szulc J, Wiznerowicz M, Sauvain MO et al. A versatile tool for conditional gene expression and knockdown. Nat Methods 2006;3:109-116.
23. Menendez P, Catalina P, Rodriguez R et al. Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene. J Exp Med 2009;206:3131-3141.
24. Rodriguez R, Rubio R, Masip M et al. Loss of p53 induces tumorigen-esis in p21-deficient mesenchymal stem cells. Neoplasia 2009;11:397-407.
25. Rubio R, Gutierrez-Aranda I, Saez-Castillo AI et al. The differentiation stage of p53-Rb-deficient bone marrow mesenchymal stem cells imposes the phenotype of in vivo sarcoma development. Oncogene 2012 Dec 10. doi:10.1038/onc.2012.507. [Epub ahead of print].
26. Rodriguez R, Gagou ME, Meuth M. Apoptosis induced by replication inhibitors in Chk1-depleted cells is dependent upon the helicase cofac-tor Cdc45. Cell Death Differ 2008;15:889-898.
27. Bueno C, Montes R, Melen GJ et al. A human ESC model for MLL-AF4 leukemic fusion gene reveals an impaired early hematopoietic-endothelial specification. Cell Res 2012;22:986-1002.
28. Gutierrez-Aranda I., Ramos-Mejia V, Bueno C et al. Human induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells regardless the site of injection. Stem Cells 2010;28:1568-1570.
29. Hashimoto H, Daimaru Y, Enjoji M. S-100 protein distribution in lipo-sarcoma. An immunoperoxidase study with special reference to the distinction of liposarcoma from myxoid malignant fibrous histiocy-toma. Virchows Arch A Pathol Anat Histopathol 1984;405:1-10.
30. Dei Tos A.P., Piccinin S, Doglioni C et al. Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma. Am J Pathol 1997;151:1531-1539.
31. Negri T, Virdis E, Brich S et al. Functional mapping of receptor tyro-sine kinases in myxoid liposarcoma. Clin Cancer Res 2010;16:3581-3593.
32. Olofsson A, Willen H, Goransson M et al. Abnormal expression of cell cycle regulators in FUS-CHOP carrying liposarcomas. Int J Oncol 2004;25:1349-1355.
33. Barretina J, Taylor BS, Banerji S et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010;42:715-721.
34. Matushansky I, Hernando E, Socci ND et al. A developmental model of sarcomagenesis defines a differentiation-based classification for lip-osarcomas. Am J Pathol 2008;172:1069-1080.
35. Farmer SR. Transcriptional control of adipocyte formation. Cell Metab 2006;4:263-273.
36. Sekiya I, Larson BL, Vuoristo JT et al. Adipogenic differentiation of human adult stem cells from bone marrow stroma (MSCs). J Bone Miner Res 2004;19:256-264.
37. Flanagan JM, Funes JM, Henderson S et al. Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets. Mol Cancer Ther 2009;8:249-260.
38. Engstrom K, Willen H, Kabjorn-Gustafsson C et al. The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells. Am J Pathol 2006;168:1642-1653.
39. Wild L, Funes JM, Boshoff C et al. In vitro transformation of mesen-chymal stem cells induces gradual genomic hypomethylation. Carcino-genesis 2010;31:1854-1862.
40. Oda Y, Yamamoto H, Takahira T et al. Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis. J Pathol 2005;207:410-421.
41. Bento C, Andersson MK, Aman P. DDIT3/CHOP and the sarcoma fusion oncoprotein FUS-DDIT3/TLS-CHOP bind cyclin-dependent kinase 2. BMC Cell Biol 2009;10:89.
42. Liu Y, Wang DL, Chen S et al. Oncogene Ras/phosphatidylinositol 3-kinase signaling targets histone H3 acetylation at lysine 56. J Biol Chem 2012;287:41469-41480.
43. Lin P, Correa D, Lin Y et al. Polybrene inhibits human mesenchymal stem cell proliferation during lentiviral transduction. PLoS One 2011; 6:e23891.
44. Molchadsky A, Rivlin N, Brosh R et al. p53 is balancing development, differentiation and de-differentiation to assure cancer prevention. Car-cinogenesis 2010;31:1501-1508.
45. Calo E, Quintero-Estades JA, Danielian PS et al. Rb regulates fate choice and lineage commitment in vivo. Nature 2010;466:1110-1114.
46. Heath VJ, Gillespie DA, Crouch DH Inhibition of the terminal stages of adipocyte differentiation by cMyc. Exp Cell Res 2000;254:91-98.
47. Murholm M, Dixen K, Hansen JB Ras signalling regulates differentiation and UCP1 expression in models of brown adipogenesis. Biochim Biophys Acta 2010;1800:619-627.
48. Goransson M, Elias E, Stahlberg A et al. Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression. Int J Cancer 2005;115:556-560.
49. Pricola KL, Kuhn NZ, Haleem-Smith H et al. Interleukin-6 maintains bone marrow-derived mesenchymal stem cell stemness by an ERK1/2-dependent mechanism. J Cell Biochem 2009;108:577-588.
50. Wood RJ. Vitamin D and adipogenesis: New molecular insights. Nutr Rev 2008;66:40-46.
51. Takada I, Kouzmenko AP, Kato S. PPAR-gamma signaling crosstalk in mesenchymal stem cells. PPAR Res 2010;2010:pii: 341671.
52. Zuniga LA, Shen WJ, Joyce-Shaikh B et al. IL-17 regulates adipogen-esis, glucose homeostasis, and obesity. J Immunol 2010;185:6947-6959.
53. Shin S, Wakabayashi N, Misra V et al. NRF2 modulates aryl hydrocarbon receptor signaling: Influence on adipogenesis. Mol Cell Biol 2007;27:7188-7197.